Fiduciary Planning’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$204K Buy
936
+3
+0.3% +$665 0.06% 75
2025
Q4
$213K Buy
933
+2
+0.2% +$456 0.06% 72
2025
Q3
$215K Buy
+931
New +$190K 0.07% 78
2022
Q1
Sell
-3,796
Closed -$514K 39
2021
Q4
$514K Sell
3,796
-7,167
-65% -$847K 0.29% 34
2021
Q3
$1.18M Sell
10,963
-1,315
-11% -$150K 0.63% 18
2021
Q2
$1.38M Sell
12,278
-5,859
-32% -$660K 1.19% 19
2021
Q1
$1.96M Buy
18,137
+532
+3% +$56.9K 2.97% 11
2020
Q4
$1.89M Buy
+17,605
New +$1.69M 2.66% 9

Other funds holding ABBV

Fiduciary Planning's ABBV Position: Q1 2026 in Review

Fiduciary Planning increased its AbbVie (ABBV) stake by 0.32% in Q1 2026, buying an estimated $665 and bringing the position to 936 shares worth $204K. The position accounts for 0.06% of the portfolio, ranked #75.

Fiduciary Planning first reported a position in ABBV in Q4 2020 and has held it in 8 quarters since. The position peaked at $1.96M in Q1 2021. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Fiduciary Planning held 936 shares of AbbVie worth $204K as of Q1 2026.
  • Fiduciary Planning bought 3 AbbVie shares in Q1 2026, an estimated $665.
  • AbbVie made up 0.06% of Fiduciary Planning's portfolio in Q1 2026, its #75 holding.
  • Fiduciary Planning first reported a position in AbbVie in Q4 2020 and has held it in 8 quarters since.
  • Fiduciary Planning's AbbVie position peaked at $1.96M in Q1 2021.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Fiduciary Planning's 13F filing for Q1 2026, filed 27 Apr 2026.